NAD+ (nicotinamide adenine dinucleotide) is arguably the most important coenzyme in cellular metabolism — it participates in over 500 enzymatic reactions, is central to mitochondrial energy production, and is consumed by sirtuins (longevity-associated enzymes), PARP proteins (DNA repair), and CD38 (an enzyme whose activity increases with aging, accelerating NAD+ depletion). Blood NAD+ levels decline approximately 50% between ages 40 and 60 in most studies. Restoring those levels is a primary target of the longevity supplement space, and two precursors dominate the market: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). The marketing war between their advocates has generated more heat than light. The clinical evidence tells a more nuanced story.
NAD+ Biosynthesis: The Pathway Debate
The biosynthetic pathway from NR to NAD+ is clearly established: NR enters cells via nucleoside transporters, is phosphorylated to NMN by NRK (nicotinamide riboside kinase) enzymes, then converted to NAD+ by NMNAT enzymes. This two-step pathway has been confirmed in yeast, rodent, and human cell culture studies.
The pathway from NMN is where controversy enters. The classical view, supported by most biochemistry, holds that NMN is too large to enter cells directly — the phosphate group prevents passive diffusion through cell membranes, and no well-characterized transporter existed for it. In this view, NMN must be converted extracellularly to NR (by CD73 enzyme activity on the cell surface) before entering cells, then reconverted to NMN and NAD+ intracellularly. If this is correct, NMN and NR are essentially interchangeable — NMN is just an expensive form of NR.
The Shin-ichiro Imai group at Washington University published a 2019 paper in Nature Metabolism identifying SLC12A8 as a putative intestinal NMN transporter, suggesting direct NMN cellular uptake may occur at least in gut tissue. This finding generated significant excitement among NMN advocates, including David Sinclair at Harvard who has publicly and commercially supported NMN. Critics — notably Charles Brenner, who invented and holds patents related to NR — point out that SLC12A8’s function has not been replicated in human tissue and that the Imai paper’s methodology has been contested. As of 2025, the transporter debate remains unresolved in peer-reviewed literature.
The practical significance for consumers: if NMN must convert to NR before entering most cells, the incremental benefit of NMN over NR is limited to any advantages in gut-specific uptake and kinetics. If the SLC12A8 transporter is validated in human tissue, direct NMN uptake would be a meaningful mechanistic advantage.
Human Clinical Trial Evidence: NR
NR has a substantially larger human clinical trial base than NMN, owing partly to its earlier commercial development and the fact that NR’s safety and pharmacokinetics were established in human studies beginning in 2016.
The foundational NR human pharmacokinetics study (Trammell et al., Cell Metabolism, 2016) demonstrated dose-dependent increases in blood NAD+ metabolomics in healthy adults at doses of 100-1000mg. The dose-response was clear: 1000mg NR per day produced approximately 2.7-fold increase in blood NAD+ levels over baseline at 7 days.
Key NR human trials: A University of Colorado Boulder study (Martens et al., Nature Communications, 2018) found that 500mg NR twice daily for 6 weeks reduced aortic stiffness and systolic blood pressure in overweight/obese adults over 55 — meaningful cardiovascular findings given that arterial stiffness is a primary aging biomarker. A separate study found NR improved muscle NAD+ levels in older adults, associated with changes in mitochondrial function markers. Multiple additional studies have examined NR in specific disease contexts: Parkinson’s, ALS, heart failure, and chronic kidney disease — all showing NAD+ replenishment with mixed disease-specific outcomes.
NR’s safety profile is well-characterized through these trials: no serious adverse events at doses up to 2000mg/day, mild GI upset occasionally reported at higher doses. Charles Brenner’s group has been rigorous in disclosing this data, including negative findings.
Human Clinical Trial Evidence: NMN
NMN human clinical trials have lagged behind NR but have gained ground rapidly. The Keio University trial (Irie et al., Endocrine Journal, 2020) was the first human NMN safety study: 10 healthy Japanese men received single oral doses from 100mg to 500mg. NMN was well-tolerated, increased blood NMN levels within 2-3 hours, and did not significantly increase blood NAD+ in this short-duration single-dose study — a finding consistent with the view that NMN converts to NR before cellular entry.
The Washington University trial (Mills et al., Science, 2021 — Imai group) is the most cited NMN human study: 25 prediabetic women ages 55-75 received 250mg NMN per day for 10 weeks. Skeletal muscle NAD+ levels increased, insulin signaling in muscle improved, and gene expression in muscle showed upregulation of pathways associated with muscle remodeling. This is a meaningful positive finding, though the study is small and sex-specific.
A Japanese clinical trial of higher-dose NMN (500mg and 1000mg/day) in healthy middle-aged adults published in Frontiers in Nutrition (2022) showed dose-dependent blood NMN increases, improved gait speed in older participants, and improved sleep quality self-report. The gait speed finding — a validated proxy for biological aging and mortality risk — is notable if replicated.
Dosing Ranges and Cost Comparison
Effective doses used in human studies: NR — 250-500mg twice daily (500-1000mg total). NMN — 250-1000mg once daily. At these doses, cost comparison matters. Quality NR at 500mg/day runs approximately $60-90/month from reputable brands (Tru Niagen is the most studied commercial NR, from ChromaDex, the NR patent holder). Quality NMN at 500mg/day runs $80-150/month depending on form factor. The premium for NMN is real but modest at comparable doses.
Liposomal and Sublingual NMN Claims
Sublingual NMN tablets and liposomal encapsulation are marketed as improving bioavailability by bypassing first-pass gut and liver metabolism. The evidence for these delivery advantages over standard NMN capsules is thin — no head-to-head human pharmacokinetic comparison between standard and sublingual NMN has been published in peer-reviewed journals as of this writing. The claims are plausible but unverified at the human trial level.
What to Look for in a Third-Party Tested Product
Certificate of Analysis (CoA) from an independent laboratory verifying NMN or NR content and purity. For NR: Tru Niagen (ChromaDex) is the most validated commercial product — their ingredient is the one used in human trials. For NMN: brands including Renue By Science, Do Not Age, and Wonderfeel have demonstrated third-party testing programs. Avoid any product claiming doses above 1000mg without corresponding human safety data.
Blood NAD+ testing is available through specialized labs (Jinfiniti Precision Medicine, Thorn) and gives a baseline and response measurement. Without testing, you are operating blind. The investment ($150-300 per test) is worthwhile over a 90-day supplementation experiment.
[ QUICK POLL // 60 SECONDS ]